Abbott Laboratories (NYSE:ABT) Stock Rating Raised to Outperform at Leerink Partners

Abbott Laboratories (NYSE:ABT – Get Free Report) was upgraded by equities researchers at Leerink Partners from a “market perform” rating to an “outperform” rating in a report released on Thursday, FinViz reports. The brokerage presently has a $124.00 price target on the healthcare product maker’s stock. Leerink Partners‘s price objective would indicate a potential upside of 18.68% from the stock’s previous close.

A number of other research analysts have also recently weighed in on the stock. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Barclays began coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Royal Bank Of Canada cut their price target on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. JPMorgan Chase & Co. reduced their price target on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, October 22nd. Finally, Argus cut Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $119.04.

Check Out Our Latest Analysis on Abbott Laboratories

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $104.48 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The stock has a market capitalization of $180.96 billion, a price-to-earnings ratio of 38.99, a PEG ratio of 1.84 and a beta of 0.54. The firm’s 50 day simple moving average is $103.88 and its 200-day simple moving average is $101.71. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $131.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. During the same period in the previous year, the business posted $1.30 EPS. The business’s revenue was up 14.5% compared to the same quarter last year. Analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Insider Activity at Abbott Laboratories

In related news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares in the company, valued at $11,691,756. This represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Abbott Laboratories

A number of large investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp grew its stake in shares of Abbott Laboratories by 0.6% in the third quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker’s stock valued at $8,047,837,000 after buying an additional 504,876 shares in the last quarter. Bank of America Corp DE purchased a new stake in Abbott Laboratories during the second quarter worth about $1,603,607,000. Deutsche Bank AG lifted its holdings in Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after buying an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Abbott Laboratories in the second quarter valued at $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Further Reading

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.